

State of Oklahoma SoonerCare



Tevimbra® (tislelizumab-jsgr) Prior Authorization Form

| Member Name: | Date of Birth: | Member ID#: |
|--|---|--|
| Drug Information | | |
| Physician billing (HCPCS code:) Start Date (or date of next dose): | | |
| ose:Regimen: | | |
| Billing Provider Information | | |
| Provider NPI: | Provider Name: | |
| Provider Phone: | Provider Fax: | |
| Prescriber Information | | |
| Prescriber NPI: Prescriber Name: | | |
| | | Specialty: |
| Criteria | | |
| B. Will Tevimbra[®] be used after C. Has member previously failed D. Will Tevimbra[®] be used as a s Gastric or Gastroesophageal A. Is diagnosis unresectable or a | metastatic esophageal so disease progression on p d other PD-1 or PD-L1 inh single agent? Yes No Junction (GEJ) Adenoca metastatic gastric or GEJ e first-line setting in combi — receptor 2 (HER2)-negati imed death ligand 1 (PD-l | arcinoma adenocarcinoma? Yes No ination with platinum and fluoropyrimidine-based ive disease? Yes No |
| Additional Information: | | |
| For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence of 3. Has member experienced any adverse reactions. | progressive disease while rse drug reactions related | · · · · · · · · · · · · · · · · · · · |
| Prescriber Signature: | | Date: |
| Prescriber Signature: Date: I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. | | |

knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 266 1/24/2025